Fc Receptor-Like Gene Expression in Renal Transplantation Patients
DOI:
https://doi.org/10.31661/gmj.v9i.1730Keywords:
Fc Receptor-Like Molecules; Kidney Transplantation; Peripheral Blood Mononuclear CellsAbstract
Background: It has been well-documented that the Fc receptor-like (FCRL) molecule contributes to the pathogenesis of certain autoimmune disorders. FCRL molecules belong to the immunoglobulin superfamily produced by B cells. Also, these molecules induce activating or inhibitory signals of B cells. According to this information and also considering the critical role of immune reactions in organ transplantation, the following experiment was performed to analyze the gene expression level of FCRLs in peripheral blood mononuclear cells of kidney transplant recipients. Materials and Methods: Blood samples were obtained from 32 renal transplant patients on days 1, 3, and 7 post-transplantations. Patients were divided into two groups according to the presence or absence of rejection. Also, 24 age-matched healthy subjects were enrolled as control group. After total RNA extraction from peripheral blood mononuclear cells (PBMC) and cDNA synthesis, the gene expression levels of FCRL1, FCRL2, and FCRL4 in each group were measured by real-time polymerase chain reaction. Results: Our results showed that FCRL1 expression levels in kidney transplant patients were significantly less than healthy controls. The overall FCRL2 expression level was not significantly different between them. However, at days 1 and 7, following transplantation in the non-rejected group FCRL2 level was significantly higher than the control group. Comparing the FCRL4 gene expression levels of both groups with healthy controls showed a significant decrease in the third and seventh days post-transplantation. Conclusion: It can be concluded that mononuclear cells, mainly B cells, have an essential role to play in kidney transplantation. [GMJ.2020;9:e1730]
References
Foss A, Heldal K, Scott H, et al. Kidneys from deceased donors more than 75 years perform acceptably after transplantation. Transplantation. 2009: 87: 1437. https://doi.org/10.1097/TP.0b013e3181a4ebd2PMid:19461478 Mendonca HM, Dos Reis MA, de Castro de Cintra Sesso R, Camara NO, Pacheco-Silva A. Renal transplantation outcomes: a comparative analysis between elderly and younger recipients. Clin Transplant. 2007: 21: 755. https://doi.org/10.1111/j.1399-0012.2007.00734.xPMid:17988270 Heinbokel T, Hock K, Liu G, Edtinger K, Elkhal A, Tulltus SG. Impact of immunosenescence on transplant outcome. Transpl Int. 2013: 26: 242.1096 https://doi.org/10.1111/tri.12013PMid:23190423 Fritsche L, Horstrup J, Budde K, Reinkeb P, Giessingc M, Tulliusd S, et al. Old-for-old kidney allocation allows successful expansion of the donor and recipient pool. Am J Transplant. 2003: 3: 1434. https://doi.org/10.1046/j.1600-6135.2003.00251.xPMid:14525606 Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010; 363(15):1451-62. https://doi.org/10.1056/NEJMra0902927PMid:20925547 BerthelotJ.M. , JaminC. , AmroucheK. , Le Goff B, Maugars Y, Youinou P., Regulatory B cells play a key role in immune system balance. Joint Bone Spine. 80 (2013) 18-22. https://doi.org/10.1016/j.jbspin.2012.04.010PMid:22858147 Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010; 10(4):236-47. https://doi.org/10.1038/nri2729PMid:20224569 PMCid:PMC3038334 Sellares J, de Freitas D.G, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012: 12(2):388-99. https://doi.org/10.1111/j.1600-6143.2011.03840.xPMid:22081892 Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009; 9(5):1099-107. https://doi.org/10.1111/j.1600-6143.2009.02591.xPMid:19422335 Aubert O, Bories MC, Suberbielle C, Snanoudj R, Anglicheau D, Rabant M, et al. Risk of antibodymediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies. Am J Transplant. 2014; 14: 1439-1445. https://doi.org/10.1111/ajt.12709PMid:24804568 Davis RS, Dennis G Jr, Odom MR, Gibson AW, Kimberly RP, Burrows PD, et al. 2002. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol. Rev. 190:123-136 https://doi.org/10.1034/j.1600-065X.2002.19009.xPMid:12493010 Davis RS, Wang YH, Kubagawa H, Cooper MD (2001) Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA. 14(98):9772-9777 https://doi.org/10.1073/pnas.171308498PMid:11493702 PMCid:PMC55528 Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R (2001) IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 14:277-289 https://doi.org/10.1016/S1074-7613(01)00109-1 Maltais LJ, Lovering RC, Taranin AV, Colonna M, Ravetch JV, Dalla-Favera R , et al. (2006) New nomenclature for Fc receptor-like molecules. Nat Immunol. 7:431-432 https://doi.org/10.1038/ni0506-431PMid:16622424 Masir N, Jones M, Pozzobon M, Marafioti T, Volkova OY, Mechetina LV, et al. (2004) Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells. Br J Haematol. 127:335-343 https://doi.org/10.1111/j.1365-2141.2004.05193.xPMid:15491296 Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, Shabani M, Memarian A, Sharifian RA, et al. (2008) Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer. 1:2113-2119 https://doi.org/10.1002/ijc.23751PMid:18704934 Yuta Kochi, Ryo Yamada, Akari Suzuki, John B. Harley, Senji Shirasawa, Tetsuji Sawada, et al. (2006) A functional variant in FCRL3, encoding Fc Receptor Homolog 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet. 37(5): 478-485 https://doi.org/10.1038/ng1540PMid:15838509 PMCid:PMC1362949 Simmonds MJ, Heward JM, Carr-Smith J, Foxall H, Franklyn JA, Gough SC (2006) Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease. J Clin Endocrinol Metab. 91:1056-1061 https://doi.org/10.1210/jc.2005-1634PMid:16384851 Jackson TA, Haga CL, Ehrhardt GR, Davis RS, Cooper MD (2010) FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells. J Immunol. 185:7405-7412 https://doi.org/10.4049/jimmunol.1002305PMid:21068405 PMCid:PMC5381824 Nückel H, Collins CH, Frey UH, Sellmann L, Dürig J, Siffert W, et al. (2009) FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia. Eur J Haematol. 1:541-549 https://doi.org/10.1111/j.1600-0609.2009.01328.xPMid:19682311 Baranov KO, Volkova OY, Mechetina L, Chikaev N, Reshetnikova E, Nikulina G, et al. (2012) Expression of human B-cell specific receptor FCRL1 in healthy individuals and in patients with autoimmune diseases. Mol Biol (Mosk). 46:500-507 https://doi.org/10.1134/S0026893312020045 Rostamzadeh D, Dabbaghmanesh MH, Shabani M, Hosseini A, Amirghofran Z (2015) Expression profile of human Fc receptor- Like 1, 2, and 4 molecules in peripheral blood mononuclear cells of patients with Hashimoto's thyroiditis and Graves' disease. Horm Metab Res. 47:693-698 https://doi.org/10.1055/s-0035-1545280PMid:25738996 Davis RS (2007) Fc receptor-like molecules. Annu Rev Immunol. 25:525-560 https://doi.org/10.1146/annurev.immunol.25.022106.141541PMid:17201682 Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, et al. (2007). A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic Lupus Erythematosus. J Immunol. 178:6624-6633 https://doi.org/10.4049/jimmunol.178.10.6624PMCid:PMC2567870
